CytoDyn DNA Vaccine Shows Promise for Low-Dose Protection from Bird Flu, Reliable Supply

SANTA FE, N.M.--(BUSINESS WIRE)--CytoDyn, Inc. (PINK SHEETS: CYDY) has completed analysis of its prospective, placebo-controlled study that used mice to compare nine variations of experimental DNA vaccines for the bird flu. Mice are the standard animal model for pre-clinical studies of human flu vaccines. Three of the vaccines given at a relatively low dose caused mice to develop antibodies against the bird flu (H2 subunit of HA H5) at a significant level (detectable at a dilution of 1:12,500). The three vaccines were: